Written byPrabha Raghavan | New Delhi |Updated: September 16, 2020 4:02:22 pm
A test tube labelled with the Vaccine is seen in front of Covid-19 and stock graph logo in this illustration taken, September 9, 2020. (Reuters)
Hyderabad-headquartered drugmaker Dr Reddy’s Laboratories (DRL) has entered into an agreement to help conduct final-stage human trials of Russia’s Sputnik V Covid-19 vaccine in India.
Once regulatory clearances are obtained, the firm will also begin to distribute up to 100 million doses for “mass vaccination” in the country.
This is the first concrete development on the Sputnik V front since India confirmed it was in discussions to take forward the testing and manufacture of the vaccine candidate that Russia cleared for public use last month.
“The Sputnik V vaccine, which is based on a well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject …